RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
01 août 2018 08h16 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial
25 juil. 2018 12h53 HE
|
Qu Biologics
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
02 juil. 2018 07h00 HE
|
RedHill Biopharma Ltd.
RedHill has received Notices of Allowance for two new patents covering RHB-104 in the U.S. and Europe which are expected to be valid until at least 2029, once granted Top-line results from the first...
Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH Grant to Advance Novel Inflammatory Bowel Disease Drug Pipeline Toward Clinical Investigation
23 mai 2018 16h03 HE
|
Thetis Pharmaceuticals LLC
BRANFORD, Conn., May 23, 2018 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing novel therapies for treatment of inflammatory bowel disease (IBD), today announced...
FDA & Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical Director
07 mai 2018 12h27 HE
|
Thetis Pharmaceuticals LLC
BRANFORD, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing first-in-class, immuno-resolving small molecule drugs to treat...
Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease
18 avr. 2018 16h16 HE
|
Qu Biologics
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique...
Regentys Names Dr. John F. Howes Vice President of Clinical and Regulatory Affairs
09 janv. 2018 07h30 HE
|
Regentys
MIAMI LAKES, Fla., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Regentys (formerly Asana Medical, Inc.) (the “Company”), a regenerative medicine company developing a novel treatment for Ulcerative Colitis...
Thetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease
16 nov. 2017 12h35 HE
|
Thetis Pharmaceuticals LLC
BRANFORD, Conn., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD),...
RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease
09 nov. 2017 07h00 HE
|
RedHill Biopharma Ltd.
Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is...
RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease
31 juil. 2017 08h00 HE
|
RedHill Biopharma Ltd.
The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the...